【券商聚焦】东方财富证券首予美丽田园医疗健康(02373)“增持”评级 指奈瑞儿并表后提供增量

金吾财讯
25 Apr

金吾财讯 | 东方财富证券发研指,美丽田园医疗健康(02373)24年实现收入25.7亿元/yoy+19.9%,内生收入22.8亿元/yoy+6.5%,实现净利润2.5亿元/yoy+9.7%;24H2实现收入14.3亿元/yoy+29.4%,内生收入11.5亿元/yoy+3.5%,外延收入(奈瑞儿并表)2.9亿元,实现归母净利润1.3亿元/yoy+16.0%。该行指,2024年24.9%的生美会员购买了医美/亚健康服务,其中28.7%的高端美容会员购买增值服务,渗透率同比+3.7pct;亚健康医疗活跃会员对直营生美业务的渗透率提升至6.1%,其中高端美容服务会员购买的亚健康医疗服务渗透率达到7.2%,渗透率同比+2.8pct,会员运营能力继续提升,多业务相互赋能挖掘消费者需求推动收入增长向好。该行续指,公司收购中国美容行业收入规模排名第二的智能美养品牌奈瑞儿,行业TOP1&TOP2的强强联合进一步提升集团市占率,24H2奈瑞儿品牌贡献收入2.9亿元,其中高端智能美养服务贡献收入1.6亿元,25年全年并表之下或将推动收入利润均保持较好增长。该行表示,预计公司2025-2027年归母净利润分别为2.7/3.2/3.7亿元,同比分别增长19.2%/16.4%/15.9%,按2025年4月23日收盘价计算的PE约13/11/10X,考虑到公司收购奈瑞儿后快速整合、优化盈利能力,证明了公司在内生品牌竞争力优势明确的基础上,亦具备较强的行业内收并购整合能力,具备一定增长确定性,首次覆盖给予“增持”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10